ENTRY       D10777                      Drug
NAME        Daratumumab (USAN);
            Daratumumab (genetical recombination) (JAN);
            Darzalex (TN)
PRODUCT     DARATUMUMAB (Janssen Biotech)
FORMULA     C6466H9996N1724O2010S42
EXACT_MASS  145300.124
MOL_WEIGHT  145389.6292
SEQUENCE    (Heavy chain)
            EVQLLESGGG LVQPGGSLRL SCAVSGFTFN SFAMSWVRQA PGKGLEWVSA ISGSGGGTYY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAKDK ILWFGEPVFD YWGQGTLVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
            YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
            RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H149-H205, H225-L214, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'214, H'266-H'326, H'372-H'430, L23-L88, L134-L194, L'23-L'88, L'134, L'194)
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            ATC code: L01FC01
            Product: D10777<JP/US>
            Product (mixture): D11967<JP/US>
EFFICACY    Antineoplastic, Anti-CD38 antibody
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Monoclonal antibody
TARGET      CD38 [HSA:952] [KO:K01242]
  PATHWAY   hsa04640(952)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FC CD38 (Clusters of Differentiation 38) inhibitors
                 L01FC01 Daratumumab
                  D10777  Daratumumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Daratumumab
                D10777  Daratumumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10777  Daratumumab (USAN); Daratumumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               ADP-ribosyl cyclase
                CD38
                 D10777  Daratumumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10777
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10777
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10777
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10777
DBLINKS     CAS: 945721-28-8
            PubChem: 313046635
///
